Akeso Completes Pricing of HK$1.2 Billion Follow-On Public Offering

Shanghai – March 28, 2024 – Cooley advised Akeso, Inc. (Hong Kong Exchange code: 9926.HK), a commercial-stage biopharmaceutical company committed to discovering, developing, manufacturing and commercializing innovative medicines that address global medical needs, on its HK$1.2 billion follow-on public offering. Lawyers Yiming Liu, Ying Liu and April Wang led the Cooley team advising Akeso, which also included Michael Yu and Yiying Wang.

Akeso offered an aggregate of 24,800,000 shares, priced at HK$47.65 per share. Proceeds from the offering will be used for the research and development of various preclinical programs advancing to investigational new drug stage, development of technology platforms, expediting the global clinical trials of key products, such as cadonilimab (AK104, PD-1/ CTLA-4) and ligufalimab (AK117, CD47), commercialization of cadonilimab and ivonescimab, and other general corporate purposes, where appropriate.

Cooley previously advised Akeso on its collaboration agreement with Pfizer in August 2021. The team also advised Akeso on its Hong Kong initial public offering in April 2020*.

* Transaction handled prior to joining Cooley.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has more than 1,300 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of nearly 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.